FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130594516> ?p ?o ?g. }

• W2130594516 endingPage "266" @default.
• W2130594516 startingPage "256" @default.
• W2130594516 abstract "Publications have reported the benefits of using high‐dose‐rate brachytherapy (HDRB) for the treatment of prostate cancer, since it provides similar biochemical control as other treatments while showing lowest long‐term complications to the organs at risk (OAR). With the inclusion of anatomy‐based inverse planning optimizers, HDRB has the advantage of potentially allowing dose escalation. Among the algorithms used, the Inverse Planning Simulated Annealing (IPSA) optimizer is widely employed since it provides adequate dose coverage, minimizing dose to the OAR, but it is known to generate large dwell times in particular positions of the catheter. As an alternative, the Hybrid Inverse treatment Planning Optimization (HIPO) algorithm was recently implemented in Oncentra Brachytherapy V. 4.3. The aim of this work was to compare, with the aid of radiobiological models, plans obtained with IPSA and HIPO to assess their use in our clinical practice. Thirty patients were calculated with IPSA and HIPO to achieve our department's clinical constraints. To evaluate their performance, dosimetric data were collected: Prostate PTV , and , Urethra , Rectum , and conformity indices. Additionally tumor control probability (TCP) and normal tissue complication probability (NTCP) were calculated with the BioSuite software. The HIPO optimization was performed firstly with Prostate PTV ( ) and then with Urethra as priority 1 ( ). Initial optimization constraints were then modified to see the effects on dosimetric parameters, TCPs, and NTCPs. HIPO optimizations could reduce TCPs up to 10%–20% for all PTVs lower than 74 cm 3 . For the urethra, IPSA and provided similar NTCPs for the majority of volume sizes, whereas resulted in large NTCP values. These findings were in agreement with dosimetric values. By increasing the PTV maximum dose constraints for plans, TCPs were found to be in agreement with IPSA without affecting the urethral NTCPs. PACS numbers: 87.55.‐x, 87.55.de, 87.55.dh, 87.53.Jw" @default.
• W2130594516 created "2016-06-24" @default.
• W2130594516 creator A5020993306 @default.
• W2130594516 creator A5043826543 @default.
• W2130594516 creator A5068502851 @default.
• W2130594516 creator A5054660758 @default.
• W2130594516 date "2014-11-01" @default.
• W2130594516 modified "2023-10-09" @default.
• W2130594516 title "Comparison of IPSA and HIPO inverse planning optimization algorithms for prostate HDR brachytherapy" @default.
• W2130594516 cites W1990510898 @default.
• W2130594516 cites W1992146492 @default.
• W2130594516 cites W2002428247 @default.
• W2130594516 cites W2002841985 @default.
• W2130594516 cites W2002847955 @default.
• W2130594516 cites W2023503398 @default.
• W2130594516 cites W2024060531 @default.
• W2130594516 cites W2026118965 @default.
• W2130594516 cites W2031966982 @default.
• W2130594516 cites W2034771449 @default.
• W2130594516 cites W2039139527 @default.
• W2130594516 cites W2055092775 @default.
• W2130594516 cites W2055203643 @default.
• W2130594516 cites W2061715500 @default.
• W2130594516 cites W2064617342 @default.
• W2130594516 cites W2076742770 @default.
• W2130594516 cites W2077234964 @default.
• W2130594516 cites W2089778115 @default.
• W2130594516 cites W2098507748 @default.
• W2130594516 cites W2111050311 @default.
• W2130594516 cites W2117792530 @default.
• W2130594516 cites W2125168442 @default.
• W2130594516 cites W2125843529 @default.
• W2130594516 cites W2135238404 @default.
• W2130594516 cites W2143381715 @default.
• W2130594516 cites W2143472867 @default.
• W2130594516 cites W2165536859 @default.
• W2130594516 cites W2171417740 @default.
• W2130594516 cites W2185593531 @default.
• W2130594516 cites W2114596588 @default.
• W2130594516 doi "https://doi.org/10.1120/jacmp.v15i6.5055" @default.
• W2130594516 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5711111" @default.
• W2130594516 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25493531" @default.
• W2130594516 hasPublicationYear "2014" @default.
• W2130594516 type Work @default.
• W2130594516 sameAs 2130594516 @default.
• W2130594516 citedByCount "26" @default.
• W2130594516 countsByYear W21305945162016 @default.
• W2130594516 countsByYear W21305945162017 @default.
• W2130594516 countsByYear W21305945162018 @default.
• W2130594516 countsByYear W21305945162019 @default.
• W2130594516 countsByYear W21305945162020 @default.
• W2130594516 countsByYear W21305945162021 @default.
• W2130594516 countsByYear W21305945162023 @default.
• W2130594516 crossrefType "journal-article" @default.
• W2130594516 hasAuthorship W2130594516A5020993306 @default.
• W2130594516 hasAuthorship W2130594516A5043826543 @default.
• W2130594516 hasAuthorship W2130594516A5054660758 @default.
• W2130594516 hasAuthorship W2130594516A5068502851 @default.
• W2130594516 hasBestOaLocation W21305945161 @default.
• W2130594516 hasConcept C11413529 @default.
• W2130594516 hasConcept C121608353 @default.
• W2130594516 hasConcept C126255220 @default.
• W2130594516 hasConcept C126322002 @default.
• W2130594516 hasConcept C126838900 @default.
• W2130594516 hasConcept C19527891 @default.
• W2130594516 hasConcept C201645570 @default.
• W2130594516 hasConcept C207467116 @default.
• W2130594516 hasConcept C2524010 @default.
• W2130594516 hasConcept C2776235491 @default.
• W2130594516 hasConcept C2777416452 @default.
• W2130594516 hasConcept C2778648096 @default.
• W2130594516 hasConcept C2780192828 @default.
• W2130594516 hasConcept C2987595161 @default.
• W2130594516 hasConcept C2989005 @default.
• W2130594516 hasConcept C33923547 @default.
• W2130594516 hasConcept C41008148 @default.
• W2130594516 hasConcept C509974204 @default.
• W2130594516 hasConcept C71924100 @default.
• W2130594516 hasConceptScore W2130594516C11413529 @default.
• W2130594516 hasConceptScore W2130594516C121608353 @default.
• W2130594516 hasConceptScore W2130594516C126255220 @default.
• W2130594516 hasConceptScore W2130594516C126322002 @default.
• W2130594516 hasConceptScore W2130594516C126838900 @default.
• W2130594516 hasConceptScore W2130594516C19527891 @default.
• W2130594516 hasConceptScore W2130594516C201645570 @default.
• W2130594516 hasConceptScore W2130594516C207467116 @default.
• W2130594516 hasConceptScore W2130594516C2524010 @default.
• W2130594516 hasConceptScore W2130594516C2776235491 @default.
• W2130594516 hasConceptScore W2130594516C2777416452 @default.
• W2130594516 hasConceptScore W2130594516C2778648096 @default.
• W2130594516 hasConceptScore W2130594516C2780192828 @default.
• W2130594516 hasConceptScore W2130594516C2987595161 @default.
• W2130594516 hasConceptScore W2130594516C2989005 @default.
• W2130594516 hasConceptScore W2130594516C33923547 @default.
• W2130594516 hasConceptScore W2130594516C41008148 @default.
• W2130594516 hasConceptScore W2130594516C509974204 @default.
• W2130594516 hasConceptScore W2130594516C71924100 @default.
• W2130594516 hasIssue "6" @default.

• next